Immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. Natural Killer cells, or NK-cells, and T-cells belong to the most potent cells of the human defense arsenal. Affimed’s proprietary, next-generation bispecific antibodies, termed TandAbs®, are designed to bring NK-cells or T-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. Due to their novel tetravalent tandem architecture, which provides for four binding domains, the TandAbs bind to specific targets on immune and cancer cells with high affinity. In addition, TandAbs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. Affimed believes, based on preclinical and clinical data generated to date, that TandAbs have the potential to ultimately improve clinical outcomes in cancer patients and could eventually become a cornerstone of modern targeted oncology care. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights.
Company Growth (employees)
Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, DE